MANKINDMankind Pharma Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · ICRA: AA+ (Stable) · CRISIL: AA+ (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.2 this quarter.
Momentum from moving averages, Supertrend and RSI.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
Forensic screen of the latest filings
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹4338 Cr | ₹716 Cr | 21.57% | 16.51% | ₹17.23 | 9.8x |
| Q1 FY2027 | ₹4031 Cr | ₹574 Cr | 20.60% | 14.24% | ₹13.76 | 8.0x |
| Q4 FY2026 | ₹3443 Cr | ₹559 Cr | 20.53% | 16.25% | ₹13.44 | 5.6x |
| Q3 FY2026 | ₹3567 Cr | ₹414 Cr | 19.53% | 11.60% | ₹9.90 | 4.2x |
| Q2 FY2026 | ₹3697 Cr | ₹520 Cr | 18.92% | 14.07% | ₹12.39 | 4.7x |
| Q1 FY2026 | ₹3570 Cr | ₹445 Cr | 17.59% | 12.45% | ₹10.62 | 4.1x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.